In vitro studies have shown that the addition of PI3K inhibitors to EGFR-TKIs can overcome resistance, and combining MEK and PI3K inhibitors has proven to be an effective therapeutic strategy for treating NSCLC with acquired resistance to EGFR-TKIs (69). Here, EGFR is linked to non-small cell lung carcinoma.